ArticleChemMedChem2026
Total Synthesis and Antimalarial Studies of Caelestines A-C.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Caelestines A-D are 2-carboxy-4-quinolones (2C4Qs) first isolated from the Australian ascidian Aplidium caelestis. The caelestines are brominated analogues of kynurenic acid and xanthurenic acid, and the only brominated 2C4Qs isolated from nature. A convenient methodology exists for the Conrad synthesis of 2C4Qs from substituted anilines and acetylene dicarboxylates cyclised in Eaton's reagent. This approach yields regioisomers from asymmetric anilines and is hampered by the absence of chromatographic methods for isolation of pure isomers. Here, we report de novo synthesis of caelestines A-C using this methodology, constituting the first reported syntheses of caelestines B and C, as well as the first reported synthesis of five other novel bromo-quinolones and three related intermediates. The first chromatographic separation of caelestine isomers yielded by Conrad synthesis is described, and structure-activity relationships of caelestines A-C (and related bromo-quinolones) against the Plasmodium falciparum 3D7 (chloroquine-sensitive) and Dd2 (chloroquine-resistant) strains are elucidated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.